NCT07544654 2026-04-22
A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
Clinical Trials
1 trialsPhase 3 × Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas × 30 days × Clear all